Anheuser-Busch InBev SA/NV

▲ Bull Case

• ◆Capital return inflection unlocks $15B+ of new shareholder value. Crossing ND/EBITDA <3.0x threshold has triggered buyback acceleration: $362M (FY23)→$937M (FY24)→$2,301M (FY25)→$6B authorization. At $82.69, buyback retires ~73M shares at 15–20% below fair value. Progressive dividend (+15–22% annually) adds 1–2% yield. Combined, total shareholder return approaches 5–6%/yr from capital deployment alone, independent of organic growth.
• ◆US recovery is observable and accelerating; Bud Light impairment is NOT terminal. Michelob Ultra is now #1 US beer by dollar share in tracked weeks; Bud Light decline rate has decelerated from free-fall to -LSD territory. Most critically, net US revenue is positive despite Bud Light weakness—demonstrating portfolio moat resilience. Management's reorientation (Michelob Ultra repositioning, increased US marketing spend) is working. Q1-26 confirms trend: +12% reported revenue with +4–5% organic in US segment implied.
• ◆Premium portfolio compounds at +6.3% CAGR while global category volumes decline -1%. Premium and super-premium tiers (Stella, Corona, Modelo Mexico, Michelob Ultra) are +6.3% growing. Mix-shift is durable (driven by EM premiumization adoption + developed-market migration to premium) and high-margin (premium carries 2–3x EBITDA per hectoliter vs. value tier). EBITDA margin expansion to 36–37% by FY28 is achievable if premium share rises from 35%→40% of revenue.

▼ Bear Case

• ◆Structural global beer-volume decline caps long-run growth; category is in slow secular decline. Global beer volumes declined -1% FY25 with mature-market headwinds: Gen Z drinking less, GLP-1 medications cited as moderation drivers, spirits/cannabis cannibalization. BUD cannot offset volume decline forever via mix-shift alone. Low/no-alcohol growing +8%–34% annually still represents <5% of category by volume. Long-run revenue CAGR will likely underperform GDP.
• ◆Bud Light impairment signals brand durability is contingent, not structural. 2023 Bud Light controversy (80% volume decline from peak; $16B brand value at risk) proved legacy megabrands can fracture if sociopolitical environment shifts. While management's recovery execution is working operationally, franchise remains psychologically fragile. A second negative catalyst (activist campaign, geopolitical event, demographic shift) could re-impair brand value, cascading to portfolio.
• ◆FX translation drag is structural and asymmetric; 85% of revenue is non-USD. BUD's reported USD results are perpetually headwinged by currency depreciation outside the US. FY25 reported revenue -0.7%, but organic +3.1%—the -3.8% gap is pure FX. Real (BRL), peso (MXN), euro volatility will persist; market consensus often underestimates FX's long-run impact. Prolonged USD strength cycle could compress reported EPS growth by 300–400 bps annually, offsetting operational improvements.

“Street consensus (10 buy / 2 hold; PT ~$89.90 vs. spot $82.69) frames BUD as 'recovery + capital-return compounder' in early innings. The variant debate is not about destination (Street and bulls broadly agree fair value ~$95–105), but path and timing. Bull variant: Capital return accelerates faster than consensus; $6B buyback completed in 18–24 months (not 3 years), compressing share count at EPS accretive prices. BEES platform value is structurally ignored in EV/EBITDA multiples; $5–10B valuation attribution would justify 14–15x vs. consensus 12x, driving upside to $110–120. Bear variant: Bud Light recovery stalls or reverses; APAC China weakness extends into FY27–28, creating structural growth headwind. Aluminum/commodity inflation resurges, pressuring gross margin, driving downside to $65–75.”

• ◆Q2-26 US segment organic revenue confirmation (Jul/Aug 2026) — Validates recovery thesis; if ≥0%, accelerates buyback case and confirms Michelob gains offset Bud Light drag
• ◆$6B buyback first $2B tranche completion (Q3-26/Q4-26) — EPS accretion 2–3% at $82–88 price (15–20% below fair value)
• ◆FY26 EBITDA margin print targeting 36%+ (Feb 2027) — Premium mix-shift confirmed; EBITDA guidance raised for FY27
• ◆ND/EBITDA milestone <2.5x achieved by FY27 (Feb 2027) — Full capital-return optionality unlocked; special dividend potential
• ◆Bud Light branded-lite stabilization: 0 LSD or better (Q4-26/Q1-27) — Brand moat durability confirmed; portfolio resilience proved

• ◆Bud Light brand re-impairment (reputational fracture, volume collapse, goodwill write-down) — CRITICAL severity, 20% probability, -$15–20/share impact; 2023 controversy demonstrated franchise fragility
• ◆Macroeconomic slowdown accelerating volume decline beyond -1% base — HIGH severity, 25% probability, -$8–12/share impact if volumes decline >2%; premium tier historically resilient in recessions
• ◆FX shock: USD strength +15% YoY (Real, peso, euro depreciation) — HIGH severity, 30% probability, -$6–10/share reported EPS impact (not intrinsic value); 85% of revenue non-USD
• ◆APAC China consumer slowdown extends into FY27–28 — MODERATE severity, 35% probability, -$4–6/share impact; China only 5% of revenue; other EM markets (India, Africa, Brazil) offsetting
• ◆Buyback pace slows below $2B/yr (capital discipline or FCF miss) — MODERATE severity, 20% probability, -$5–8/share on 2–3 year thesis; FCF generation is durable at 53% EBITDA conversion